Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 1L

ssessment Status Rapid Review Complete
Drug Pembrolizumab
Brand Keytruda®
Indication For the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.
Assessment Process
Rapid review commissioned 06/12/2017
Rapid review completed 21/12/2017
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Following an amendment of the product licence by the EMA, a new rapid review was commissioned by the HSE.
Rapid review commissioned 21/06/2018
Rapid review received 10/07/2018
Rapid review completed 27/07/2018
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies

The HSE has approved reimbursement following confidential price negotiations – February 2021.